Sympathetic nervous system and arterial hypertension: New perspectives, new data

Kardiologia Polska

Volumn 71, Issue 5, 2013, Pages 441-446

  Hering, Dagmara ^a   Narkiewicz, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; NORADRENALIN;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; BRAIN DEPTH STIMULATION; CAROTID SINUS PRESSORECEPTOR; DISEASE COURSE; ESSENTIAL HYPERTENSION; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY; KIDNEY ARTERY STENOSIS; KIDNEY DENERVATION; MUSCLE SYMPATHETIC NERVE ACTIVITY; NORADRENALIN RELEASE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRESSORECEPTOR; QUALITY OF LIFE; REVIEW; STENT; SYMPATHETIC TONE;

EID: 84878925263     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: 10.5603/KP.2013.0089     Document Type: Review

References (50)

1. Hering D, Esler MD, Krum H et al. Recent advances in the treatment of hypertension. Expert Rev Cardiovasc Ther, 2011; 9: 729-744.
2. Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: analysis of worldwide data. Lancet, 2005; 365: 217-223.
3. Bertoia ML, Waring ME, Gupta PS et al. Implications of new hypertension guidelines in the United States. Hypertension, 2012; 60: 639-644.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ et al. Executive summary: heart disease and stroke statistics: 2013 update: a report from the american heart association. Circulation, 2013; 127: 143-152.
5. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 2008; 51: 1403-1419.
6. Pierdomenico SD, Lapenna D, Bucci A et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens, 2005; 18: 1422-148.
7. Witkowski A, Januszewicz A, Imiela J et al. Catheter-based renal sympathetic denervation for the treatment of resistant arterial hypertension in Poland: experts consensus statement. Kardiol Pol, 2011; 69: 1208-1211.
8. Daugherty SL, Powers JD, Magid DJ et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation, 2012; 125: 1635-1642.
9. Daugherty SL, Powers JD, Magid DJ et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension, 2012; 60: 303-309.
10. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet, 2002; 360: 1903-1913.
11. Esler M, Jennings G, Biviano B et al. Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol, 1986; 8 (suppl. 5): S39-S43.
12. Julius S, Nesbitt S. Sympathetic overactivity in hypertension. A moving target. Am J Hypertens, 1996; 9: 113S-120S.
13. Greenwood JP, Stoker JB, Mary DA. Single-unit sympathetic discharge: quantitative assessment in human hypertensive disease. Circulation, 1999; 100: 1305-1310.
14. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension, 1999; 34: 724-728.
15. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans. Evidence from direct intraneural recordings. Hypertension 1989; 14: 177-183.
16. Esler M, Lambert G, Jennings G. Regional norepinephrine turnover in human hypertension. Clin Exp Hypertens A, 1989; 11 (suppl. 1): 75-89.
17. Schlaich MP, Lambert E, Kaye DM et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension, 2004; 43: 169-175.
18. Hering D, Kara T, Kucharska W et al. High-normal blood pressure is associated with increased resting sympathetic activity but normal responses to stress tests. Blood Press, 2013; Jan 23 [Epub ahead of print].
19. Schlaich MP, Kaye DM, Lambert E et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation, 2003; 108: 560-565.
20. Grassi G, Seravalle G, Quarti-Trevano F et al. Sympathetic and baroreflex cardiovascular control in hypertension-related left ventricular dysfunction. Hypertension, 2009; 53: 205-209.
21. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation, 2002; 105: 1354-1359.
22. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med, 2009; 361: 932-934.
23. Hering D, Lambert EA, Marusic P et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension, 2013; 61: 457-464.
24. Narkiewicz K. Układ współczulny a nadciśnienie tȩtnicze. Via Medica, Gdańsk 2001.
25. Parmer RJ, Cervenka JH, Stone RA. Baroreflex sensitivity and heredity in essential hypertension. Circulation, 1992; 85: 497-503.
26. Rea RF, Hamdan M. Baroreflex control of muscle sympathetic nerve activity in borderline hypertension. Circulation, 1990; 82: 856-862.
27. Trzebski A, Tafil M, Zoltowski M, Przybylski J. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension. Cardiovasc Res, 1982; 16: 163-172.
28. Somers VK, Mark AL, Abboud FM. Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension, 1988; 11: 608-612.
29. Sinski M, Lewandowski J, Przybylski J et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res, 2012; 35: 487-491.
30. Ferrier C, Esler MD, Eisenhofer G et al. Increased norepinephrine spillover into the jugular veins in essential hypertension. Hypertension, 1992; 19: 62-69.
31. DiBona GF. The sympathetic nervous system and hypertension: recent developments. Hypertension, 2004; 43: 147-150.
32. Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens, 2012; 30: 837-841.
33. Parati G IJJ, Gavish B. Respiration and blood pressure. Chapter A43. In: Izzo JL, Sica D, Black HR eds. Hypertension primer. 4th Ed. Lippincott, Williams, and Wilkins, Baltimore 2008: 136-138.
34. Oneda B, Ortega KC, Gusmao JL, Araujo TG, Mion D, Jr. Sympathetic nerve activity is decreased during device-guided slow breathing. Hypertens Res, 2010; 33: 708-712.
35. Hering D, Kucharska W, Kara T et al. Effects of acute and long-term slow breathing exercise on muscle sympathetic nerve activity in untreated male patients with hypertension. J Hypertens, 2013; 31: 739-746.
36. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, 2009; 373: 1275-1281.
37. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet, 2010; 376: 1903-1909.
38. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension, 2011; 57: 911-917.
39. Brandt MC, Mahfoud F, Reda S et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol, 2012; 59: 901-909.
40. Mortensen K, Franzen K, Himmel F et al. Catheter-based renal sympathetic denervation improves central hemodynamics and arterial stiffness: a pilot study. J Clin Hypertens (Greenwich), 2012; 14: 861-870.
41. Hering D, Walton A, Krum H et al. Renal nerve ablation reduces blood pressure in a patient with renovascular hypertension resistant to drug and revascularisation therapies. Int J Cardiol, 2012; 159: e35-e36.
42. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension, 2011; 58: 559-565.
43. Hering D, Esler MD, Schlaich MP. Effects of renal denervation on insulin resistance. Expert Rev Cardiovasc Ther, 2012; 10: 1381-1386.
44. Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol, 2012; 23: 1250-1257.
45. Lambert GW, Hering D, Esler MD et al. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension, 2012; 60: 1479-1484.
46. Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol, 2010; 56: 1254-1258.
47. Bakris GL, Nadim MK, Haller H et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens, 2012; 6: 152-158.
48. Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension, 2010; 55: 619-626.
49. Pereira EA, Wang S, Paterson DJ et al. Sustained reduction of hypertension by deep brain stimulation. J Clin Neurosci, 2010; 17: 124-127.
50. Patel NK, Javed S, Khan S et al. Deep brain stimulation relieves refractory hypertension. Neurology, 2011; 76: 405-407.